July 21, 2004 — Cetuximab is effective for irinotecan-resistant colon cancer alone or in combination with irinotecan, according to the results of a randomized trial published in the July 22 issue of ...

Cetuximab combined with chemotherapy significantly improves PFS and OS in mCRC patients, as confirmed by a meta-analysis of 25 studies. The study highlights cetuximab's efficacy, despite limitations ...

April 3, 2012 — Adding the targeted agent cetuximab (Erbitux, Bristol-Myers Squibb) to the current standard mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimen in patients with ...

Prognostic factors of overall survival for patients with stage II colon cancer treated at Sparrow Hospital from 1996–2006 No significant financial relationships to disclose. This is an ASCO Meeting ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Maintenance ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

A combination of adagrasib, a small-molecule KRAS inhibitor, and cetuximab, an anti-EGFR antibody, demonstrated promising clinical activity and tolerable safety in heavily pretreated patients with ...

The FDA granted accelerated approval to adagrasib (Krazati) for KRAS G12C-mutated colorectal cancer (CRC), which accounts for 3-5% of CRCs. The approval stipulates use of adagrasib in combination with ...

Regina Andrijes, Rahul K. Hejmadi, Matthew Pugh, Sundaresan Rajesh, Vera Novitskaya, Maha Ibrahim, Michael Overduin, Chris Tselepis, Gary W. Middleton, Balázs Győrffy, Andrew D. Beggs, Fedor ...

There’s been an exciting new development for some patients with metastatic colorectal cancer: a groundbreaking FDA approval has introduced a new treatment option specifically designed for those with ...